{"id":1663,"text":"Drug transporters play important roles in the absorption, distribution, and elimination of drugs and thereby, modulate drug efficacy and toxicity.","label":[[0,17,"Parameter"],[46,96,"Parameter"],[137,145,"Pathology"]],"Comments":[]}
{"id":1664,"text":"With a growing use of poly pharmacy, concurrent administration of herbal extracts that modulate transporter activities with drugs can cause serious adverse reactions.","label":[[66,81,"Herb name"],[96,118,"Parameter"],[148,165,"Pathology"]],"Comments":[]}
{"id":1665,"text":"Therefore, prediction and evaluation of drug-drug interaction potential is important in the clinic and in the drug development process.","label":[],"Comments":[]}
{"id":1666,"text":"DA-9801, comprising a mixed extract of Dioscoreae rhizoma and Dioscorea nipponica Makino, is a new standardized extract currently being evaluated for diabetic peripheral neuropathy in a phase II clinical study.","label":[[0,88,"Herb name"],[99,119,"Extraction process"],[150,180,"Pathology"],[184,209,"Study"]],"Comments":[]}
{"id":1667,"text":"The inhibitory effects of DA-9801 on the transport functions of organic cation transporter (OCT)1, OCT2, organic anion transporter (OAT)1, OAT3, organic anion transporting polypeptide (OATP)1B1, OATP1B3, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) were investigated in HEK293 or LLC-PK1 cells.","label":[[26,33,"Herb name"],[37,270,"Parameter"],[231,244,"Pathology"]],"Comments":[]}
{"id":1668,"text":"The effects of DA-9801 on the pharmacokinetics of relevant substrate drugs of these transporters were also examined in vivo in rats.","label":[[15,22,"Herb name"],[26,96,"Parameter"]],"Comments":[]}
{"id":1669,"text":"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC Inhibitory effects of DA-9801 on OCT1, OCT2, and OAT3 observed in vitro may not necessarily translate into in vivo herb-drug interactions in rats even at its maximum effective dose.","label":[[0,7,"Herb name"],[31,84,"Parameter"],[55,84,"Target"],[116,123,"Herb name"],[127,147,"Target"],[252,274,"Parameter"]],"Comments":[]}
{"id":1670,"text":"Diabetic peripheral neuropathy is one of the most debilitating complications of type 1 and type 2 diabetes and its histopathology is characterized by axonal degeneration, demyelination, and atrophy [1,2].","label":[[0,30,"Pathology"],[80,106,"Pathology"],[150,197,"Pathology"]],"Comments":[]}
{"id":1671,"text":"Approximately 50% of diabetes patients have symptoms of diabetic peripheral neuropathy [3].","label":[[21,29,"Pathology"],[44,86,"Pathology"]],"Comments":[]}
{"id":1672,"text":"The pursuit of new drugs for the treatment of diabetic peripheral neuropathy has led to the identification of DA-9801, an ethanol extract of Dioscoreae rhizoma and Dioscorea nipponica Makino, as a potential therapeutic agent; it is currently being evaluated in a phase II diabetic neuropathy clinical study in Korea [4].","label":[[46,76,"Pathology"],[110,117,"Herb name"],[119,137,"Extraction process"],[141,190,"Herb name"],[261,306,"Study"],[272,291,"Pathology"]],"Comments":[]}
{"id":1673,"text":"DA-9801 may improve diabetic neuropathy-induced tissue damage by increasing nerve growth factor levels in target tissues, improving nerve conduction velocity, and promoting recovery from neuronal degeneration [4,5].","label":[[0,7,"Herb name"],[20,61,"Pathology"],[76,102,"Parameter"],[132,157,"Parameter"],[187,208,"Pathology"]],"Comments":[]}
{"id":1674,"text":"It also showed neuroprotective effects on peripheral nerves in streptozotocin-induced diabetic rats [6,7].","label":[[63,77,"Drug"],[86,94,"Pathology"]],"Comments":[]}
{"id":1675,"text":"Herb-drug interactions, resulting from concurrent use of herbal drugs may cause adverse reactions such as toxicity and treatment failure [8].","label":[[57,69,"Herb name"],[80,97,"Pathology"],[106,114,"Pathology"]],"Comments":[]}
{"id":1676,"text":"The mechanisms underlying herb-drug interactions involve inhibition or induction of cytochrome P450 (CYP) enzymes, UDP-glucuronosyltransferase (UGT) enzymes, and drug transporters [9,10].","label":[[84,179,"Target"]],"Comments":[]}
{"id":1677,"text":"St. John’s wort (Hypericum perforatum), ginkgo (Ginko biloba), ginseng (Panax ginseng), milk thistle (Silybum marianum), and licorice (Glycyrrhiza glabra) have been reported to cause drug interactions with anticoagulants, antiretroviral drugs, anticancer drugs, immunosuppressants, or antidepressants [11-15].","label":[[0,154,"Herb name"],[206,300,"Drug"]],"Comments":[]}
{"id":1678,"text":"Therefore, it is necessary to evaluate herb-drug interactions in order to prevent potentially dangerous clinical outcomes.","label":[[94,121,"Pathology"]],"Comments":[]}
{"id":1679,"text":"DA-9801 did not potently inhibit CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 and UGT 1A1, 1A4, 1A9, or 2B7 in human liver microsomes, indicating that DA-9801 may not inhibit the metabolism of CYP- and UGT-catalyzed drugs in humans [8].","label":[[0,7,"Herb name"],[33,109,"Target"],[153,160,"Herb name"],[177,223,"Parameter"]],"Comments":[]}
{"id":1680,"text":"In this study, we investigated possible herb-drug interactions involving drug transporters by using HEK293 and LLC-PK1 cell systems overexpressing clinically important uptake and efflux transporters such as organic cation transporter (OCT) 1, OCT2, organic anion transporter (OAT) 1, OAT3, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, P-glycoprotein (P-gp or MDR1), and breast cancer resistance protein (BCRP) [16].","label":[[73,90,"Parameter"],[168,424,"Parameter"],[385,398,"Pathology"]],"Comments":[]}
{"id":1681,"text":"We also investigated the effects of DA-9801 on the pharmacokinetics of substrates for the effected transporters in vivo in rats.","label":[[36,43,"Herb name"],[47,111,"Parameter"]],"Comments":[]}
{"id":1682,"text":"Dried Dioscoreae rhizoma and rhizome of Dioscorea nipponica Makino were purchased at a speciality market for traditional herbal medicine (Dong Kyung Pharm.","label":[[0,66,"Herb name"],[17,24,"Herb part"],[29,36,"Herb part"],[109,136,"Herb name"]],"Comments":[]}
{"id":1683,"text":"Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).","label":[],"Comments":[]}
{"id":1684,"text":"The voucher specimens for Dioscoreae rhizoma (deposit code, KNJS) and rhizome of Dioscorea nipponica Makino (deposit code, LY026) were deposited at Dong-A ST Research Center (Youngin, Korea).","label":[[26,44,"Herb name"],[37,44,"Herb part"],[70,77,"Herb part"],[70,107,"Herb name"]],"Comments":[]}
{"id":1685,"text":"DA-9801 was prepared as previously reported [5].","label":[[0,7,"Herb name"]],"Comments":[]}
{"id":1686,"text":"Briefly, dried Dioscoreae rhizoma and rhizome of Dioscorea nipponica Makino were mixed in a specific ratio (3.5:1) and extracted with 50% ethanol three times at room temperature for 48 h. After filtration, the aqueous ethanol extract was evaporated under reduced pressure and lyophilized to completely remove the residual solvent and to yield brown powder.","label":[[9,75,"Herb name"],[26,33,"Herb part"],[38,45,"Herb part"],[134,137,"Amount"],[134,145,"Extraction process"],[146,157,"Amount"],[161,177,"Parameter"],[178,186,"Duration"],[206,233,"Extraction process"],[343,355,"Extraction process"]],"Comments":[]}
{"id":1687,"text":"The levels of two marker components - dioscin (1.37%) and allantoin (3.29%) - in DA-9801 were determined using high performance liquid chromatography [5].","label":[[38,75,"Herb name"],[81,88,"Herb name"]],"Comments":[]}
{"id":1688,"text":"[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).","label":[[42,99,"Parameter"]],"Comments":[]}
{"id":1689,"text":"The cells were maintained at 37°C in a humidified atmosphere of 8% CO LLC-PK1-MDR1 (LLC-PK1 cells stably expressing P-gp; purchased from Corning-Gentest) and LLC-PK1-BCRP (LLC-PK1 cells stably expressing BCRP; obtained from Dr. A.H. Schinkel, Netherlands Cancer Institute, Amsterdam, The Netherlands) cells were used for the comparison of the basal to apical (B to A) transport rate of [ Sprague–Dawley (SD) rats (male, 7 weeks old) were obtained from Samtako Co. (Osan, Korea).","label":[[29,31,"Amount"],[31,33,"Parameter"],[39,69,"Parameter"],[64,66,"Amount"],[116,120,"Parameter"],[204,208,"Parameter"],[368,382,"Parameter"],[414,418,"Sex"],[420,431,"Age"]],"Comments":[]}
{"id":1690,"text":"Animals were acclimated for 1 week in a temperature controlled room (23 ± 2°C), with a relative humidity of 55 ± 10%, an illumination intensity of 150–300 lux, a frequency of air ventilation of 15–20 times\/h, and a 12 h illumination (07:00–19:00).","label":[[24,34,"Duration"],[40,51,"Parameter"],[69,77,"Amount"],[96,104,"Parameter"],[108,116,"Amount"],[121,143,"Parameter"],[147,158,"Amount"],[160,207,"Frequency"],[215,245,"Duration"]],"Comments":[]}
{"id":1691,"text":"Food and water were supplied ad libitum.","label":[],"Comments":[]}
{"id":1692,"text":"All animal procedures were approved by the Animal Care and Use Committee in The Catholic University of Korea.","label":[],"Comments":[]}
{"id":1693,"text":"Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.","label":[[119,129,"Parameter"],[135,145,"Drug"]],"Comments":[]}
{"id":1694,"text":"Each rat was housed individually in a rat metabolic cage and allowed to recover from anesthesia.","label":[[85,95,"Parameter"]],"Comments":[]}
{"id":1695,"text":"The rats were not restrained at any time during the study.","label":[],"Comments":[]}
{"id":1696,"text":"Heparinized isotonic saline (10 U\/mL) was used to flush the catheters to prevent blood clotting.","label":[[0,27,"Extraction process"],[29,36,"Amount"],[81,95,"Pathology"]],"Comments":[]}
{"id":1697,"text":"The rats were fasted for more than 12 h before oral administration of drugs.","label":[[14,20,"Parameter"],[35,39,"Duration"]],"Comments":[]}
{"id":1698,"text":"DA-9801 was dissolved in DMSO\/propylene glycol\/deionized water (2:6:2, v\/v), and a 1,000 mg\/kg dose was administered to the rats by oral gavages (vehicle dosing volume, 3 mL\/kg) at 5 min and 2 h prior to the oral administration of cimetidine at a dose of 10 mg\/kg [18] and furosemide at a dose of 10 mg\/kg [19] (vehicle dosing volume, 2 mL\/kg).","label":[[0,7,"Herb name"],[25,75,"Extraction process"],[83,94,"Amount"],[181,186,"Duration"],[191,194,"Duration"],[231,241,"Drug"],[255,263,"Amount"],[273,283,"Drug"],[297,305,"Amount"]],"Comments":[]}
{"id":1699,"text":"Cimetidine and furosemide were dissolved in deionized water and DMSO\/propylene glycol\/deionized water (2:4:4, v\/v\/v), respectively.","label":[[0,10,"Drug"],[15,25,"Drug"],[44,116,"Extraction process"]],"Comments":[]}
{"id":1700,"text":"Blood samples were collected prior to cimetidine and furosemide administration (to serve as a control), 5, 15, 30, 45 min, and 1, 1.5, 2, 3, 4, 6, 8 h after oral administration of cimetidine and furosemide.","label":[[38,48,"Drug"],[53,63,"Drug"],[104,156,"Duration"],[180,190,"Drug"],[195,205,"Drug"]],"Comments":[]}
{"id":1701,"text":"After centrifugation of blood samples at 13,000 rpm for 5 min, plasma samples (30 μL) were collected and stored at -80°C until analysis.","label":[[52,61,"Duration"],[115,118,"Amount"],[118,120,"Parameter"]],"Comments":[]}
{"id":1702,"text":"At 24 h after drug administration, the metabolic cage was rinsed with distilled water (10 mL), and the rinsed solutions were combined with the pooled urine samples collected for 24 h. After measuring the exact volume of the urine samples, 30 μL aliquots of each sample were stored at -20°C until analysis.","label":[[3,13,"Duration"],[70,86,"Extraction process"],[87,92,"Amount"],[178,182,"Duration"],[284,287,"Amount"],[287,289,"Parameter"]],"Comments":[]}
{"id":1703,"text":"The concentrations of cimetidine were analyzed using a modified liquid chromatography tandem mass spectrometry (LC-MS\/MS) method reported by Sun et al.","label":[[0,32,"Parameter"],[22,32,"Drug"]],"Comments":[]}
{"id":1704,"text":"[20].","label":[],"Comments":[]}
{"id":1705,"text":"Thirty μL of rat plasma samples, calibration standards, and quality control (QC) samples were vortex-mixed with 100 μL of tiapride in methanol (5 ng\/mL, internal standard, IS) for 3 min at a high speed.","label":[[112,118,"Amount"],[122,130,"Drug"],[134,142,"Extraction process"],[144,151,"Amount"],[176,185,"Duration"]],"Comments":[]}
{"id":1706,"text":"After centrifugation at 13,000 rpm at 4°C for 8 min, 50 μL of the supernatant was diluted with 50 μL of water.","label":[[38,39,"Amount"],[39,41,"Parameter"],[42,51,"Duration"],[95,100,"Amount"],[104,109,"Extraction process"]],"Comments":[]}
{"id":1707,"text":"An aliquot (3 μL) was injected into the LC-MS\/MS system.","label":[],"Comments":[]}
{"id":1708,"text":"Ten μL of rat urine samples, urine calibration standards, and QC samples were vortex-mixed with 1,000 μL of tiapride in methanol (5 μg\/mL) for 3 min at high speed.","label":[[96,104,"Amount"],[108,116,"Drug"],[120,128,"Extraction process"],[130,137,"Amount"],[139,148,"Duration"]],"Comments":[]}
{"id":1709,"text":"After centrifugation at 13,000 rpm at 4°C for 8 min, 10 μL of the supernatant was diluted with 200 μL of 30% methanol and an aliquot (3 μL) was injected into the LC-MS\/MS system.","label":[[38,39,"Amount"],[39,41,"Parameter"],[42,51,"Duration"],[95,101,"Amount"],[105,117,"Extraction process"]],"Comments":[]}
{"id":1710,"text":"Plasma calibration standards were 1–1000 ng\/mL and urine calibration standards were 1–200 μg\/mL.","label":[[0,28,"Parameter"],[34,46,"Amount"],[51,78,"Parameter"],[84,95,"Amount"]],"Comments":[]}
{"id":1711,"text":"The LC-MS\/MS system consisted of an Agilent 1200 series (Agilent Technologies, Wilmington, DE, USA) and a 6460 triple quadrupole mass spectrometer (Agilent Technologies).","label":[],"Comments":[]}
{"id":1712,"text":"Mass Hunter software (Agilent Technologies) was used for LC-MS\/MS system control and data processing.","label":[],"Comments":[]}
{"id":1713,"text":"Separation was performed on a Luna phenyl-hexyl column (5 μm, 2.1 mm i.d.","label":[],"Comments":[]}
{"id":1714,"text":"× 100 mm, Phenomenex, Torrance, CA, USA) with a gradient elution of 5% methanol with 10 mM ammonium formate (mobile phase A) and 95% methanol with 10 mM ammonium formate (mobile phase B) at a flow rate of 0.4 mL\/min: 30% mobile phase B for 0.5 min, 30% to 85% mobile phase B for 0.5 min, 85% mobile phase B for 3.0 min, 85% to 30% mobile phase B for 0.1 min, 30% mobile phase B for 4 min.","label":[[68,70,"Amount"],[71,79,"Extraction process"],[85,90,"Amount"],[91,107,"Extraction process"],[129,132,"Amount"],[133,141,"Extraction process"],[147,152,"Amount"],[153,169,"Extraction process"],[205,215,"Frequency"],[236,247,"Duration"],[275,286,"Duration"],[307,318,"Duration"],[346,357,"Duration"],[378,387,"Duration"]],"Comments":[]}
{"id":1715,"text":"The column and autosampler were maintained at 50°C and 5°C, respectively.","label":[[46,48,"Amount"],[48,50,"Parameter"],[55,56,"Amount"],[56,58,"Parameter"]],"Comments":[]}
{"id":1716,"text":"Electrospray ionization (ESI) source settings for ionization of cimetidine in the positive mode were as follows: gas temperature, 350°C; gas flow, 10 L\/min; nebulizer, 35 psi; sheath gas temperature, 330°C; sheath gas flow, 11 L\/min, and capillary voltage, 3500 V. Fragmentation of molecular ions for cimetidine and tiapride was performed at a collision energy of 10 eV and 18 eV, respectively.","label":[[64,74,"Drug"],[130,133,"Amount"],[133,135,"Parameter"],[147,155,"Frequency"],[200,203,"Amount"],[203,205,"Parameter"],[224,232,"Frequency"],[301,311,"Drug"],[316,324,"Drug"]],"Comments":[]}
{"id":1717,"text":"Selected reaction monitoring (SRM) mode was used for quantification: m\/z 253.1 → 159.1 for cimetidine and m\/z 329.1 → 256 for tiapride.","label":[[91,101,"Drug"],[126,134,"Drug"]],"Comments":[]}
{"id":1718,"text":"The concentrations of furosemide were analyzed using a modified LC-MS\/MS method reported by Sora et al.","label":[[0,32,"Parameter"],[22,32,"Drug"]],"Comments":[]}
{"id":1719,"text":"[21].","label":[],"Comments":[]}
{"id":1720,"text":"Thirty μL of rat plasma samples, calibration standards, and QC samples were vortex-mixed with 100 μL of 4-hydroxydiclofenac-d In the inhibition studies, the percentages of inhibition were calculated using the ratio of the transport rate of probe substrates with or without DA-9801 and the relevant data were fitted to an inhibitory effect model [i.e.","label":[[94,100,"Amount"],[104,125,"Drug"],[240,256,"Parameter"],[273,280,"Herb name"]],"Comments":[]}
{"id":1721,"text":"In the in vivo rat studies, non-compartmental pharmacokinetic analysis was also performed using the WinNonlin software.","label":[[7,26,"Study"]],"Comments":[]}
{"id":1722,"text":"The area under the plasma concentration–time curve (AUC) was calculated using the linear trapezoidal method.","label":[[0,56,"Parameter"]],"Comments":[]}
{"id":1723,"text":"The area from the last datum point to time infinity (AUC Statistical significance was analyzed using the Mann–Whitney U test, and values of p < 0.05 were considered statistically significant.","label":[[0,56,"Parameter"]],"Comments":[]}
{"id":1724,"text":"The SPSS software package (ver.","label":[],"Comments":[]}
{"id":1725,"text":"19.0, SPSS, Chicago, IL) was used for statistical analysis.","label":[],"Comments":[]}
{"id":1726,"text":"To characterize the inhibitory effect of DA-9801 on the uptake transporters, we measured the uptake of representative substrates for each transporter in HEK293 cells overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 in the presence of DA-9801 (1–300 μg\/mL).","label":[[41,48,"Herb name"],[52,75,"Target"],[89,149,"Parameter"],[181,225,"Parameter"],[245,252,"Herb name"]],"Comments":[]}
{"id":1727,"text":"DA-9801 inhibited the transport activity of OCT1, OCT2, OAT3, and OATP1B1 with IC Inhibitory effect of DA-9801 on the transport activities of OCT1 (A), OCT2 (B), OAT1 (C), OAT3 (D), OATP1B1 (E), OATP1B3 (F), P-gp (G), and BCRP (H).","label":[[0,7,"Herb name"],[44,73,"Target"],[103,110,"Herb name"],[114,226,"Parameter"],[142,226,"Target"]],"Comments":[]}
{"id":1728,"text":"Inhibitory effect of DA-9801 (1–300 μg\/ml) on the uptake of 0.1 μM [ To assess the relevance of the DA-9801 IC The AUC Pharmacokinetic parameters of cimetidine (10 mg\/kg) after co-administration of DA-9801 at a single oral dose of 1,000 mg\/kg *p < 0.05, for the comparison with the control group.","label":[[21,28,"Herb name"],[30,41,"Amount"],[60,67,"Amount"],[100,107,"Herb name"],[111,159,"Parameter"],[149,159,"Drug"],[161,169,"Amount"],[198,205,"Herb name"],[211,227,"Frequency"],[231,242,"Amount"]],"Comments":[]}
{"id":1729,"text":"**p <0.01, for the comparison with control group.","label":[],"Comments":[]}
{"id":1730,"text":"Plasma concentration-time curves of cimetidine.","label":[[0,46,"Parameter"],[36,46,"Drug"]],"Comments":[]}
{"id":1731,"text":"(A) Plasma concentration profile of cimetidine in rats after oral administration of 10 mg\/kg cimetidine alone (●) and cimetidine with 5 min pre-dose of 1,000 mg\/kg DA-9801 (○).","label":[[4,46,"Parameter"],[36,46,"Drug"],[84,92,"Amount"],[93,103,"Drug"],[118,128,"Drug"],[134,139,"Duration"],[152,163,"Amount"],[164,171,"Herb name"]],"Comments":[]}
{"id":1732,"text":"(B) Plasma concentration profile of cimetidine in rats after oral administration of 10 mg\/kg cimetidine alone (●) and cimetidine with 2 h pre-dose of 1,000 mg\/kg DA-9801 (○).","label":[[4,46,"Parameter"],[36,46,"Drug"],[84,92,"Amount"],[93,103,"Drug"],[118,128,"Drug"],[134,137,"Duration"],[150,161,"Amount"],[162,169,"Herb name"]],"Comments":[]}
{"id":1733,"text":"Each data point represents the mean ± S.D.","label":[],"Comments":[]}
{"id":1734,"text":"of five rats.","label":[],"Comments":[]}
{"id":1735,"text":"In contrast to these cimetidine-related observation, the pharmacokinetic parameters such as T Pharmacokinetic parameters of furosemide (10 mg\/kg) after co-administration of DA-9801 at a single oral dose of 1,000 mg\/kg Plasma concentration-time curves of furosemide.","label":[[21,31,"Drug"],[54,93,"Parameter"],[94,134,"Parameter"],[124,134,"Drug"],[136,144,"Amount"],[173,180,"Herb name"],[184,202,"Frequency"],[206,217,"Amount"],[218,264,"Parameter"],[254,264,"Drug"]],"Comments":[]}
{"id":1736,"text":"(A) Plasma concentration profile of furosemide in rats after oral administration of 10 mg\/kg furosemide alone (●) and furosemide with 5 min pre-dose of 1,000 mg\/kg DA-9801 (○).","label":[[4,46,"Parameter"],[36,46,"Drug"],[84,92,"Amount"],[93,103,"Drug"],[118,128,"Drug"],[134,139,"Duration"],[152,163,"Amount"],[164,171,"Herb name"]],"Comments":[]}
{"id":1737,"text":"(B) Plasma concentration profile of furosemide in rats after oral administration of 10 mg\/kg furosemide alone (●) and furosemide with 2 h pre-dose of 1,000 mg\/kg DA-9801 (○).","label":[[4,46,"Parameter"],[36,46,"Drug"],[84,92,"Amount"],[93,103,"Drug"],[118,128,"Drug"],[134,137,"Duration"],[150,161,"Amount"],[162,169,"Herb name"]],"Comments":[]}
{"id":1738,"text":"Each data point represents the mean ± S.D.","label":[],"Comments":[]}
{"id":1739,"text":"of five rats.","label":[],"Comments":[]}
{"id":1740,"text":"The recent trend toward the use of poly pharmacy, which comprises drugs with different mechanisms of action, necessitates careful consideration of the potential drug-drug interactions (DDI) between the combined medicines.","label":[],"Comments":[]}
{"id":1741,"text":"DDIs between inhibitors and substrates of metabolizing enzymes or transporters can cause serious adverse reactions.","label":[[13,78,"Parameter"],[97,114,"Pathology"]],"Comments":[]}
{"id":1742,"text":"Therefore, prediction and evaluation of DDI potential is important in the clinic and in the drug development process.","label":[],"Comments":[]}
{"id":1743,"text":"It is increasingly recognized that drug transporters have a significant impact on DDIs by modulating the absorption, distribution, and excretion of drugs, alone or in interaction with drug-metabolizing enzymes [16,25,26].","label":[[35,52,"Parameter"],[100,153,"Parameter"]],"Comments":[]}
{"id":1744,"text":"In particular, screening of clinically important drug transporters such as OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3, P-gp, and BCRP in the drug development stage is recommended [16].","label":[[49,131,"Parameter"]],"Comments":[]}
{"id":1745,"text":"In this study, we investigated the inhibitory effects of DA-9801 on these transporters.","label":[[57,64,"Herb name"]],"Comments":[]}
{"id":1746,"text":"IC It is important to note that in vivo human studies investigating the interactions between DA-9801 and substrates for the affected transporters such as OCT1, OCT2, and OAT3 are necessary to determine whether the in vitro inhibition of these transporters by DA-9801 is relevant or not.","label":[[32,53,"Study"],[93,100,"Herb name"],[105,174,"Parameter"],[259,266,"Herb name"]],"Comments":[]}
{"id":1747,"text":"The inhibition of transport activities in vitro can be applied to herb-drug interaction potential in vivo with effective highest plasma concentration, plasma free fraction, and IC The effective dose of DA-9801 for the therapeutics of diabetic neuropathy was 100–1,000 mg\/kg in rats [6,7].","label":[[18,38,"Parameter"],[129,171,"Parameter"],[180,209,"Parameter"],[202,209,"Herb name"],[234,253,"Pathology"],[258,273,"Amount"]],"Comments":[]}
{"id":1748,"text":"Therefore, we treated DA-9801 at a dose of 1,000 mg\/kg in this study since the inhibitor has been treated at a maximum effective dose to investigate the highest possibility of in vivo herb-drug interaction.","label":[[22,29,"Herb name"],[43,54,"Amount"],[109,133,"Parameter"]],"Comments":[]}
{"id":1749,"text":"Then, although the experimental systems and species were not perfectly matched, after determining the IC Cimetidine is a H2 receptor antagonist used for the treatment of peptic ulcers and related disorders.","label":[[105,143,"Drug"],[170,205,"Pathology"]],"Comments":[]}
{"id":1750,"text":"It is eliminated mainly by renal excretion in rats, with 70% eliminated by 72 h after oral ingestion without significant metabolism [29].","label":[[27,42,"Parameter"],[57,60,"Amount"],[75,79,"Duration"]],"Comments":[]}
{"id":1751,"text":"Cimetidine undergoes extensive tubular secretion in which Oct1\/2 and Oat3 play major roles [23].","label":[[0,10,"Drug"],[31,48,"Parameter"],[58,73,"Parameter"]],"Comments":[]}
{"id":1752,"text":"In case of 5 min pre-dose of DA-9801, C Furosemide, an inhibitor of the Na We have investigated the inhibitory effects of DA-9801 on transport activities of clinically important transporters and explored the in vivo herb-drug interaction potential between DA-9801 and target transporters such as OCT1, OCT2, and OAT3 at the maximum effective dose of DA-9801 in rats (1,000 mg\/kg).","label":[[11,16,"Duration"],[29,36,"Herb name"],[40,74,"Drug"],[122,129,"Herb name"],[134,190,"Parameter"],[256,263,"Herb name"],[268,316,"Parameter"],[320,357,"Parameter"],[350,357,"Herb name"],[367,378,"Amount"]],"Comments":[]}
{"id":1753,"text":"While DA-9801 pre-dose (5 min or 2 h) did not change the pharmacokinetics of furosemide, it decreased the C The authors have declared that no competing interests exist.","label":[[6,13,"Herb name"],[24,36,"Duration"],[77,87,"Drug"]],"Comments":[]}
{"id":1754,"text":"Conceived and designed the experiments: ISS, HEK, SZC, MS, HSL.","label":[],"Comments":[]}
{"id":1755,"text":"Performed the experiments: ISS, TYK, HYJ, ENK, SSK.","label":[],"Comments":[]}
{"id":1756,"text":"Analyzed the data: ISS, TYK, HUJ, ENK, SSK, HEK, SZC, MS, HSL.","label":[],"Comments":[]}
{"id":1757,"text":"Wrote the paper: ISS, TYK, HUJ, ENK, SSK, HEK, SZC, MS, HSL.","label":[],"Comments":[]}
{"id":1758,"text":"All authors read and approved the final manuscript.","label":[],"Comments":[]}
{"id":1759,"text":"The pre-publication history for this paper can be accessed here:           This work was supported by the Global Leading Technology Program of the Office of Strategic R&D Planning (OSP), funded by the Ministry of Knowledge Economy (MKE), Republic of Korea (10039303) and The Catholic University of Korea, 2011 (M-2011-B0002-00046).","label":[],"Comments":[]}
